Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) ##STR00001## in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a --NR.sub.1R.sub.2 amino group in which R.sub.1 and R.sub.2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a --NR.sub.3R.sub.4R.sub.5 quaternary ammonium group in which R.sub.3, R.sub.4, R.sub.5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.